Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism.

ABSTRACT:

Objective

Topiramate has been shown to reduce drinking and heavy drinking in individuals with alcohol dependence whose goal was to stop drinking. The authors evaluated the efficacy and tolerability of topiramate in heavy drinkers whose treatment goal was to reduce drinking to safe levels.

Method

A total of 138 individuals (62.3% men) were randomly assigned to receive 12 weeks of treatment with topiramate (N=67), at a maximal daily dose of 200 mg, or matching placebo (N=71). Both groups received brief counseling to reduce drinking and increase abstinent days. It was hypothesized that topiramate-treated patients would be better able to achieve these goals, and it was predicted that based on prior research, the effects would be moderated by a single nucleotide polymorphism (rs2

SUBMITTER: Kranzler HR 

PROVIDER: S-EPMC3997125 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature